Developer docs
API playgroundTry for free, no card

Search company profiles

Sol-Gel Technologies

Full company profile

uuid0004g65

Namestring
Sol-Gel Technologies
Legal namestring
SOL-GEL Technologies Ltd.
Websiteurl
sol-gel.com
Company typeenum
Public
Founded yearint
1997
Descriptiontext

Sol-Gel Technologies Ltd. is a clinical-stage and commercial dermatology company headquartered in Ness Ziona, Israel, and listed on NASDAQ under ticker SLGL. The company develops topical pharmaceutical products using a proprietary microencapsulation and formulation platform that enables novel local delivery while limiting systemic exposure. Its portfolio spans two FDA-approved marketed products — TWYNEO (tretinoin 0.1% / benzoyl peroxide 3% cream for acne vulgaris) and EPSOLAY (encapsulated benzoyl peroxide 5% cream for rosacea) — and two clinical-stage assets: SGT-610, a topical 2% patidegib gel in Phase 3 for prevention of new basal cell carcinoma lesions in Gorlin syndrome (with Orphan Drug and FDA Breakthrough Therapy designations); and SGT-210, a topical erlotinib platform being evaluated in feasibility studies after a December 2025 Darier disease failure. Sol-Gel holds EU and FDA Orphan Drug status on patidegib and Breakthrough Therapy designation on the same molecule.

The company operates a capital-light, asset-light business model with 51–100 employees and no commercial sales force. Revenue is generated through licensing royalties and milestone payments from established pharmaceutical partners — primarily Galderma, which holds US commercialization rights to TWYNEO and EPSOLAY, plus Mayne Pharma and Search Light Pharma for Canada. Q1 2026 reported revenue was $108K versus $900K consensus, indicating that the current licensing streams remain de minimis. The controlling shareholder is Arkin Dermatology (Arkin family), with Chairman/CEO Moshe Arkin leading a small executive team and a board that includes former Perrigo and Given Imaging CFOs. The company is funded to advance SGT-610 through its pivotal Phase 3 readout expected in Q4 2026.

Short descriptiontext

Sol-Gel Technologies is a clinical-stage Israeli dermatology company (NASDAQ: SLGL) developing topical microencapsulation-based drugs for rare and common skin conditions, including lead Phase 3 candidate SGT-610 for Gorlin syndrome and FDA-approved TWYNEO and EPSOLAY licensed to Galderma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNess Ziona, Israel
HQ citystring
Ness Ziona
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
topical dermatology drugs, specialty pharmaceuticals, rare skin disease treatments, microencapsulation formulations, dermatology drug licensing
Industry3 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIADAE
Dermatology & Topical Skin Treatments
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Specialty Dermatology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Royalties - TWYNEO
TypeLicensing Royalties
Description

TWYNEO is licensed to Galderma for US commercialization. Sol-Gel receives royalties on sales.

sol-gel.com
2Licensing Royalties - EPSOLAY
TypeLicensing Royalties
Description

EPSOLAY is licensed to Galderma for US commercialization. Sol-Gel receives royalties on sales.

sol-gel.com
3Development Milestones
TypeLicensing Royalties
Description

Potential milestone payments from licensing partners tied to development and regulatory milestones.

globenewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1TWYNEO
Description

Topical treatment for acne vulgaris - first and only FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide (BPO) for adults and pediatric patients 9 years and older.

sol-gel.com
+1 more record
Core offering1 text field

Sol-Gel Technologies develops and licenses topical dermatological pharmaceutical products, including two FDA-approved products (TWYNEO for acne vulgaris and EPSOLAY for inflammatory lesions of rosacea) and a pipeline targeting rare skin conditions such as Gorlin syndrome. The company leverages proprietary microencapsulation technology to create novel topical formulations and out-licenses commercialization rights to established dermatology companies including Galderma.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sol-Gel Technologies is a dermatology company developing a portfolio of topical pharmaceutical products spanning both rare skin conditions and common dermatological indications. The pipeline includes SGT-610 (patidegib gel, Phase III) and SGT-210 (topical erlotinib, Phase I completed) as investigational candidates targeting Gorlin syndrome, high-frequency BCC, and keratinization disorders. The commercial portfolio consists of two FDA-approved products licensed to Galderma: TWYNEO (tretinoin and benzoyl peroxide cream for acne) and EPSOLAY (encapsulated benzoyl peroxide cream for rosacea). The company leverages proprietary microencapsulation technology to develop topical formulations that enhance drug delivery and minimize systemic exposure.

Product and service4 records
1TWYNEO
CategoryMarketed dermatology product
Description

The first and only FDA-approved fixed-dose combination of tretinoin (0.1%) and benzoyl peroxide (3%) for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. Marketed in the US by Galderma and planned for availability in Canada.

2EPSOLAY
CategoryMarketed dermatology product
Description

The first and only FDA-approved encapsulated benzoyl peroxide (5%) topical cream for the treatment of inflammatory lesions of rosacea in adults. Marketed in the US and planned for availability in Canada.

3SGT-610
CategoryInvestigational drug candidate
Description

A topically applied 2% patidegib gel, Sol-Gel's lead pipeline candidate for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome. A topical hedgehog pathway inhibitor leveraging a unique formulation with minimal risk for systemic adverse events; granted FDA Orphan Drug and Breakthrough Therapy designations.

4SGT-210
CategoryInvestigational drug candidate
Description

A topical erlotinib drug candidate platform designed to enable local EGFR inhibition while limiting systemic exposure. Used in compassionate care for Olmsted syndrome.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

TWYNEO will be available in Canada through Mayne Pharma, with planned launch in early 2024.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-07-27
Description

TWYNEO and EPSOLAY are licensed to Galderma for US commercialization. Galderma handles all marketing, distribution and sales activities for these products in the US market. This is Sol-Gel's primary commercial partnership for its approved products.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

TWYNEO will be available in Canada through Search Light Pharma partnership.

4Gorlin Syndrome Alliance
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sol-Gel partnered with the Gorlin Syndrome Alliance to support, educate, and empower patients and their loved ones as they navigate this condition. This patient advocacy partnership is important for clinical trial recruitment and disease awareness.

sol-gel.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arcutis is a US-listed dermatology-focused biopharma developing and commercializing topical treatments for inflammatory skin diseases. It overlaps directly with Sol-Gel in topical formulation R&D, dermatology pipeline strategy, and similar scale/go-to-market profile.

TypeDirect peer
Description

Verrica is a US dermatology specialty pharma focused on topical therapies for skin diseases including molluscum and common warts. It is comparable to Sol-Gel in being a small-cap, US-listed dermatology company with prescription topical products and similar capitalization range.

TypeDirect peer
Description

Aclaris is a clinical-stage dermatology biopharmaceutical company developing immunomodulatory and topical therapies for skin and immune-mediated diseases. It matches Sol-Gel as a small-cap, dermatology-focused innovator with both approved and pipeline assets.

TypeDirect peer
Description

Dermavant is a Roivant-backed dermatology company developing topical therapies for inflammatory skin conditions. It is comparable to Sol-Gel in its topical dermatology pipeline focus and similar stage of commercialization.

TypeDirect peer
Description

Biofrontera is a dermatology company specializing in topical photodynamic therapies and prescription skin treatments. It overlaps with Sol-Gel in the prescription topical dermatology category and similar small/mid-cap profile.

TypeBroad incumbent
Description

Galderma is the world's largest pure-play dermatology company and Sol-Gel's key US commercialization partner for TWYNEO and EPSOLAY. It is comparable as a broad dermatology incumbent with overlapping topical product portfolios and significantly greater scale.

TypeBroad incumbent
Description

Almirall is a European dermatology-focused pharmaceutical company with a broad prescription dermatology portfolio. It is comparable to Sol-Gel as a dermatology-specialist incumbent with topical and systemic treatments across multiple indications.

TypeEmerging player
Description

Novan is a clinical-stage dermatology company developing nitric oxide-based topical therapies for skin diseases. It is comparable to Sol-Gel as a small, emerging topical dermatology innovator with pipeline-stage assets.

TypeOthers
Description

Anacor was a US dermatology-focused biopharma (acquired by Pfizer in 2016) that developed boron-based topical therapies. It is included as a historical comparable showing the typical exit pathway for small-cap topical dermatology innovators like Sol-Gel.

10Cassiopea
TypeOthers
Description

Cassiopea was a dermatology specialty company (acquired by Cosmo Pharmaceuticals) that developed prescription topical treatments including for acne. It is included as a historical small-cap dermatology peer and acquisition comparable for Sol-Gel.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sol-Gel Technologies

Specialty Dermatology Pharmaceuticalssol-gel.com

Sol-Gel Technologies is a clinical-stage Israeli dermatology company (NASDAQ: SLGL) developing topical microencapsulation-based drugs for rare and common skin conditions, including lead Phase 3 candidate SGT-610 for Gorlin syndrome and FDA-approved TWYNEO and EPSOLAY licensed to Galderma.

What Sol-Gel Technologies does

Sol-Gel Technologies Ltd. is a clinical-stage and commercial dermatology company headquartered in Ness Ziona, Israel, and listed on NASDAQ under ticker SLGL. The company develops topical pharmaceutical products using a proprietary microencapsulation and formulation platform that enables novel local delivery while limiting systemic exposure. Its portfolio spans two FDA-approved marketed products — TWYNEO (tretinoin 0.1% / benzoyl peroxide 3% cream for acne vulgaris) and EPSOLAY (encapsulated benzoyl peroxide 5% cream for rosacea) — and two clinical-stage assets: SGT-610, a topical 2% patidegib gel in Phase 3 for prevention of new basal cell carcinoma lesions in Gorlin syndrome (with Orphan Drug and FDA Breakthrough Therapy designations); and SGT-210, a topical erlotinib platform being evaluated in feasibility studies after a December 2025 Darier disease failure. Sol-Gel holds EU and FDA Orphan Drug status on patidegib and Breakthrough Therapy designation on the same molecule.

The company operates a capital-light, asset-light business model with 51–100 employees and no commercial sales force. Revenue is generated through licensing royalties and milestone payments from established pharmaceutical partners — primarily Galderma, which holds US commercialization rights to TWYNEO and EPSOLAY, plus Mayne Pharma and Search Light Pharma for Canada. Q1 2026 reported revenue was $108K versus $900K consensus, indicating that the current licensing streams remain de minimis. The controlling shareholder is Arkin Dermatology (Arkin family), with Chairman/CEO Moshe Arkin leading a small executive team and a board that includes former Perrigo and Given Imaging CFOs. The company is funded to advance SGT-610 through its pivotal Phase 3 readout expected in Q4 2026.

Sol-Gel Technologies firmographics

Firmographics
Name
Sol-Gel Technologies
Legal name
SOL-GEL Technologies Ltd.
Website
https://sol-gel.com
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Sol-Gel Technologies is a clinical-stage Israeli dermatology company (NASDAQ: SLGL) developing topical microencapsulation-based drugs for rare and common skin conditions, including lead Phase 3 candidate SGT-610 for Gorlin syndrome and FDA-approved TWYNEO and EPSOLAY licensed to Galderma.
Ownership category
akta.pro rank

Sol-Gel Technologies industry classification

Industry
Product category
Specialty Dermatology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIADAE
Dermatology & Topical Skin Treatments
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Topical dermatology drugs
  • Specialty pharmaceuticals
  • Rare skin disease treatments
  • Microencapsulation formulations
  • Dermatology drug licensing

Where Sol-Gel Technologies is headquartered

Location

Headquarters

HQ city
Ness Ziona
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Sol-Gel Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing Royalties - TWYNEO: TWYNEO is licensed to Galderma for US commercialization. Sol-Gel receives royalties on sales.
  2. Licensing Royalties - EPSOLAY: EPSOLAY is licensed to Galderma for US commercialization. Sol-Gel receives royalties on sales.
  3. Development Milestones: Potential milestone payments from licensing partners tied to development and regulatory milestones.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Sol-Gel Technologies product offering

Product offering

Core offering

Sol-Gel Technologies develops and licenses topical dermatological pharmaceutical products, including two FDA-approved products (TWYNEO for acne vulgaris and EPSOLAY for inflammatory lesions of rosacea) and a pipeline targeting rare skin conditions such as Gorlin syndrome. The company leverages proprietary microencapsulation technology to create novel topical formulations and out-licenses commercialization rights to established dermatology companies including Galderma.

Product overview

Sol-Gel Technologies is a dermatology company developing a portfolio of topical pharmaceutical products spanning both rare skin conditions and common dermatological indications. The pipeline includes SGT-610 (patidegib gel, Phase III) and SGT-210 (topical erlotinib, Phase I completed) as investigational candidates targeting Gorlin syndrome, high-frequency BCC, and keratinization disorders. The commercial portfolio consists of two FDA-approved products licensed to Galderma: TWYNEO (tretinoin and benzoyl peroxide cream for acne) and EPSOLAY (encapsulated benzoyl peroxide cream for rosacea). The company leverages proprietary microencapsulation technology to develop topical formulations that enhance drug delivery and minimize systemic exposure.

Differentiator

Problem solved

Functional benefit

Brands

  • TWYNEO: Topical treatment for acne vulgaris - first and only FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide (BPO) for adults and pediatric patients 9 years and older.
  • EPSOLAY

Products and services

  • TWYNEO The first and only FDA-approved fixed-dose combination of tretinoin (0.1%) and benzoyl peroxide (3%) for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. Marketed in the US by Galderma and planned for availability in Canada.
  • EPSOLAY The first and only FDA-approved encapsulated benzoyl peroxide (5%) topical cream for the treatment of inflammatory lesions of rosacea in adults. Marketed in the US and planned for availability in Canada.
  • SGT-610 A topically applied 2% patidegib gel, Sol-Gel's lead pipeline candidate for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome. A topical hedgehog pathway inhibitor leveraging a unique formulation with minimal risk for systemic adverse events; granted FDA Orphan Drug and Breakthrough Therapy designations.
  • SGT-210 A topical erlotinib drug candidate platform designed to enable local EGFR inhibition while limiting systemic exposure. Used in compassionate care for Olmsted syndrome.

Companies that use Sol-Gel Technologies

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles1 record

Sol-Gel Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Sol-Gel Technologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Mayne PharmacoreChannel Partner/ Reseller/ Distributor · 1 January 2024TWYNEO will be available in Canada through Mayne Pharma, with planned launch in early 2024.
  • GaldermacoreChannel Partner/ Reseller/ Distributor · 27 July 2021TWYNEO and EPSOLAY are licensed to Galderma for US commercialization. Galderma handles all marketing, distribution and sales activities for these products in the US market. This is Sol-Gel's primary commercial partnership for its approved products.
  • Search Light PharmacoreChannel Partner/ Reseller/ DistributorTWYNEO will be available in Canada through Search Light Pharma partnership.
  • Gorlin Syndrome AlliancecoreStrategic or Co-development PartnerSol-Gel partnered with the Gorlin Syndrome Alliance to support, educate, and empower patients and their loved ones as they navigate this condition. This patient advocacy partnership is important for clinical trial recruitment and disease awareness.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Sol-Gel Technologies competitors and assessment

Company assessment

Direct peers

  • Arcutis Biotherapeutics: Arcutis is a US-listed dermatology-focused biopharma developing and commercializing topical treatments for inflammatory skin diseases. It overlaps directly with Sol-Gel in topical formulation R&D, dermatology pipeline strategy, and similar scale/go-to-market profile.
  • Verrica Pharmaceuticals: Verrica is a US dermatology specialty pharma focused on topical therapies for skin diseases including molluscum and common warts. It is comparable to Sol-Gel in being a small-cap, US-listed dermatology company with prescription topical products and similar capitalization range.
  • Aclaris Therapeutics: Aclaris is a clinical-stage dermatology biopharmaceutical company developing immunomodulatory and topical therapies for skin and immune-mediated diseases. It matches Sol-Gel as a small-cap, dermatology-focused innovator with both approved and pipeline assets.
  • Dermavant Sciences: Dermavant is a Roivant-backed dermatology company developing topical therapies for inflammatory skin conditions. It is comparable to Sol-Gel in its topical dermatology pipeline focus and similar stage of commercialization.
  • Biofrontera: Biofrontera is a dermatology company specializing in topical photodynamic therapies and prescription skin treatments. It overlaps with Sol-Gel in the prescription topical dermatology category and similar small/mid-cap profile.

Broad incumbents

  • Galderma: Galderma is the world's largest pure-play dermatology company and Sol-Gel's key US commercialization partner for TWYNEO and EPSOLAY. It is comparable as a broad dermatology incumbent with overlapping topical product portfolios and significantly greater scale.
  • Almirall: Almirall is a European dermatology-focused pharmaceutical company with a broad prescription dermatology portfolio. It is comparable to Sol-Gel as a dermatology-specialist incumbent with topical and systemic treatments across multiple indications.

Emerging players

  • Novan: Novan is a clinical-stage dermatology company developing nitric oxide-based topical therapies for skin diseases. It is comparable to Sol-Gel as a small, emerging topical dermatology innovator with pipeline-stage assets.

Others

  • Anacor Pharmaceuticals: Anacor was a US dermatology-focused biopharma (acquired by Pfizer in 2016) that developed boron-based topical therapies. It is included as a historical comparable showing the typical exit pathway for small-cap topical dermatology innovators like Sol-Gel.
  • Cassiopea: Cassiopea was a dermatology specialty company (acquired by Cosmo Pharmaceuticals) that developed prescription topical treatments including for acne. It is included as a historical small-cap dermatology peer and acquisition comparable for Sol-Gel.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Sol-Gel Technologies social profiles

Digital presence

Sol-Gel Technologies compliance and trust

Trust signal

Compliance2 records

Sol-Gel Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sol-Gel Technologies leadership team

Management profile

Number of profiles

Profiles11 records

Sol-Gel Technologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sol-Gel Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sol-Gel Technologies

What does Sol-Gel Technologies do?

Sol-Gel Technologies develops and licenses topical dermatological pharmaceutical products, including two FDA-approved products (TWYNEO for acne vulgaris and EPSOLAY for inflammatory lesions of rosacea) and a pipeline targeting rare skin conditions such as Gorlin syndrome. The company leverages proprietary microencapsulation technology to create novel topical formulations and out-licenses commercialization rights to established dermatology companies including Galderma.

Is Sol-Gel Technologies a public or private company?

Sol-Gel Technologies is a public company. It is classified as public and is currently operating.

When was Sol-Gel Technologies founded?

Sol-Gel Technologies was founded in 1997. It employs 11 to 50 people.

Where is Sol-Gel Technologies based?

Sol-Gel Technologies is headquartered in Ness Ziona, Israel, in the Middle East region.

How does Sol-Gel Technologies make money?

Three revenue lines are on record. Licensing Royalties - TWYNEO is the primary driver. The others are licensing Royalties - EPSOLAY and development Milestones.

Who are Sol-Gel Technologies's main competitors?

Direct peers on record are Arcutis Biotherapeutics, Verrica Pharmaceuticals, Aclaris Therapeutics, Dermavant Sciences and Biofrontera. Broad incumbents are Galderma and Almirall. Novan is listed as an emerging player. Others are Anacor Pharmaceuticals and Cassiopea.

Does Sol-Gel Technologies have an API?

No public API is recorded for Sol-Gel Technologies.

What industry is Sol-Gel Technologies in?

Sol-Gel Technologies's product category is Specialty Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldSol-Gel Technologies (NASDAQ:SLGL) vs. BioAge Labs (NASDAQ:BIOA) Critical ContrastSol-Gel Technologies and BioAge Labs are compared on profitability, institutional ownership, and analyst ratings. Sol-Gel has higher revenue and earnings but lower analyst upside, while BioAge has higher probable upside. Sol-Gel beats BioAge on 8 of 15 factors.Quiver QuantitativeSOL GEL TECHNOLOGS ($SLGL) Releases Q3 2026 Earnings | SLGL Stock NewsSOL GEL TECHNOLOGS reported Q3 2026 earnings of -$1.72 per share, beating estimates of -$2.11, but revenue of $41,000 missed estimates of $153,000. The stock fell 10.74% after market open. Insiders made 19 purchases in the past six months, and 12 institutional investors added shares while 8 reduced positions.MarketBeatSol-Gel Technologies Ltd. (NASDAQ:SLGL) Stock Now Rated "Buy" by Wall Street BrokeragesSol-Gel Technologies shares received a consensus Buy rating from seven analysts, with an average 12-month price target of $197.50. The company reported a loss of $1.13 per share for the quarter, beating estimates, and insiders bought 53,430 shares in the last 90 days.American Banking and Market NewsCritical Survey: Iterum Therapeutics (NASDAQ:ITRM) vs. Sol-Gel Technologies (NASDAQ:SLGL)Sol-Gel Technologies beats Iterum Therapeutics on 10 of 15 factors, including higher revenue and a lower price-to-earnings ratio. Analysts rate Sol-Gel more favorably with a consensus target price of $197.50, implying a 207.39% upside. Institutional ownership is higher for Sol-Gel at 26.2% versus 9.2% for Iterum.American Banking and Market NewsSol-Gel Technologies (NASDAQ:SLGL) Given Buy Rating at HC WainwrightHC Wainwright reissued a buy rating on Sol-Gel Technologies with a $110 price target, implying 71.21% upside. The stock opened at $64.25, and the company reported a loss of $1.13 per share, beating estimates. Analysts have a consensus Buy rating with an average price target of $197.50.MarketBeatSol-Gel Technologies (NASDAQ:SLGL) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a Buy rating on Sol-Gel Technologies with a $110 price target, implying 71.21% upside. The company reported Q2 EPS of -$1.13, beating estimates of -$2.36, and revenue of $0.59 million. Analysts have a consensus Buy rating with an average price target of $197.50.TradingViewHC Wainwright & Co. reiterates Buy rating on Sol-Gel Technologies, $110 price targetHC Wainwright reiterated a Buy rating on Sol-Gel Technologies with a $110 price target, implying a 71.2% upside from the Oct 16 close of $64.25. The note cites favorable commercial outlook for SGT-610 and an upcoming Phase 3 trial readout as key catalysts.American Banking and Market NewsHC Wainwright Reaffirms “Buy” Rating for Sol-Gel Technologies (NASDAQ:SLGL)HC Wainwright reaffirmed a buy rating on Sol-Gel Technologies with a $110 target, implying 67.15% upside. The stock rose 1.3% to $65.81, while the company reported a loss of $1.13 EPS, beating estimates. Analysts' consensus remains buy with a $197.50 target.American Banking and Market NewsSol-Gel Technologies (NASDAQ:SLGL) Stock Keeps Buy Rating at HC WainwrightHC Wainwright reiterated a buy rating on Sol-Gel Technologies with a $110 target, implying 67.82% upside from the previous close. The stock traded up $0.57 to $65.55, and analysts have an average rating of Buy with a $197.50 target. The company reported a loss of $1.13 EPS for the quarter, beating estimates.American Banking and Market NewsSol-Gel Technologies’ (SLGL) “Buy” Rating Reiterated at HC WainwrightHC Wainwright reiterated a buy rating on Sol-Gel Technologies with a $110 target, implying 67.26% upside. The stock rose $0.79 to $65.77, and major shareholder Opaleye Management bought 35,113 shares at $69.32. Analysts average a buy rating with a $197.50 target.